Me-PB-Hyos Elixir and Telavancin Hydrochloride

• Generic Name: atropine / hyoscyamine / phenobarbital / scopolamine
• Dosage Forms: oral liquid
• Other Brand Names: Donnatal, D-Tal, Phenohytro, Chardonna-2, Hyosophen, Donnapine, Elixiral, Bellatal, Spasmolin, Haponal, Antispas, Barbidonna, Donnatal Extentabs, Antispasmodic, Bellalphen, Donnaphen, Spasquid, Alkabel-SR, Bellatal ER, Servira, PB-Hyos, Quadrapax, Phenobarbital with Belladonna Alkaloids

Menveo (meningococcal conjugate vaccine) is used to prevent meningococcal disease, an infection caused by meningococcal bacteria. These bacteria can infect the spinal cord and brain, causing meningitis that can be fatal. Meningococcal disease can also lead to permanent and disabling medical problems.

Meningococcal disease can spread from one person to another through small droplets of saliva that are expelled into the air when an infected person coughs or sneezes. The bacteria can also be passed through contact with objects the infected person has touched, such as a door handle or other surface. The bacteria can also be passed through kissing, or sharing a drinking glass or eating utensil with an infected person.

Meningococcal disease is more likely to occur in babies younger than 1 year, in young people ages 16 to 23 years, in anyone with a weak immune system, and in anyone exposed to an outbreak of the disease.

Menveo works by exposing you to a small dose of the bacteria or a protein from the bacteria, which causes your body to develop immunity to the disease. Menveo contains four of the most common types of meningococcal bacteria (serogroups A, C, W, and Y).

Meningococcal vaccine will not treat an active meningococcal infection that has already developed in the body.

Menveo is for use in children and adults between the ages of 9 months and 55 years old.

Like any vaccine, Menveo may not provide protection from disease in every person.

• Generic Name: telavancin
• Dosage Forms: n.a.
• Other Brand Names: Vibativ

Treatment of nosocomial pneumonia, including hospital-acquired and ventilator-associated pneumonia, caused by susceptible Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA; also known as oxacillin-resistant S. aureus or ORSA]).

If documented or presumed pathogens also include gram-negative or anaerobic bacteria, concomitant use of an anti-infective active against such bacteria may be clinically indicated.

Manufacturer states reserve telavancin for use when alternative treatments for hospital-acquired or ventilator-associated bacterial pneumonia not suitable.

Skin and Skin Structure Infections

Treatment of complicated skin and skin structure infections caused by susceptible S. aureus (including MRSA), Streptococcus pyogenes (group A β-hemolytic streptococci, GAS), S. agalactiae (group B streptococci, GBS), S. anginosus group (includes S. anginosus, S. intermedius, S. constellatus), or Enterococcus faecalis (vancomycin-susceptible strains only).

If documented or presumed pathogens also include gram-negative or anaerobic bacteria, concomitant use of an anti-infective active against such bacteria may be clinically indicated.